COVID-19 mortality in patients on anticoagulants and antiplatelet agents.
作者信息
Sivaloganathan Helena, Ladikou Eleni E, Chevassut Timothy
机构信息
Brighton and Sussex Medical School, University of Sussex, Brighton, UK.
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
出版信息
Br J Haematol. 2020 Aug;190(4):e192-e195. doi: 10.1111/bjh.16968. Epub 2020 Jul 19.
Abstract
摘要
相似文献
1
COVID-19 mortality in patients on anticoagulants and antiplatelet agents.使用抗凝剂和抗血小板药物的患者的新冠病毒疾病死亡率
Br J Haematol. 2020 Aug;190(4):e192-e195. doi: 10.1111/bjh.16968. Epub 2020 Jul 19.
2
Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis.COVID-19 患者中中剂量抗凝、阿司匹林与住院死亡率：倾向评分匹配分析。
Am J Hematol. 2021 Apr 1;96(4):471-479. doi: 10.1002/ajh.26102. Epub 2021 Feb 22.
3
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population.床旁血栓弹力图快速评估新冠病毒病患者中抗凝剂和阿司匹林的药效学反应：在以少数族裔为主的人群中治疗不足的证据
J Thromb Thrombolysis. 2021 May;51(4):902-904. doi: 10.1007/s11239-021-02435-1. Epub 2021 Apr 7.
4
The effect of current antithrombotic therapy on mortality in nursing home residents with COVID-19: a multicentre retrospective cohort study.当前抗血栓治疗对 COVID-19 养老院居民死亡率的影响：一项多中心回顾性队列研究。
Age Ageing. 2024 May 1;53(5). doi: 10.1093/ageing/afae094.
5
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review.COVID-19 治疗中联合使用抗凝和抗血小板药物的作用：快速综述。
Open Heart. 2021 Jun;8(1). doi: 10.1136/openhrt-2021-001628.
6
Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis.COVID-19 住院患者抗凝剂量与生存的相关性：一项回顾性倾向评分加权分析。
Eur J Haematol. 2021 Feb;106(2):165-174. doi: 10.1111/ejh.13533. Epub 2020 Nov 4.
7
"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": reply.《2023年国际血栓与止血学会（ISTH）对2022年COVID-19抗栓治疗ISTH指南的更新》：回复
J Thromb Haemost. 2024 Sep;22(9):2672-2673. doi: 10.1016/j.jtha.2024.06.009.
8
Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants.抗血小板或抗凝药物治疗患者的下消化道出血再出血和死亡率。
Clin Gastroenterol Hepatol. 2019 Jun;17(7):1276-1284.e3. doi: 10.1016/j.cgh.2017.12.032. Epub 2017 Dec 23.
9
Antiplatelet Therapy in Patients With COVID-19-More Is Less?新冠病毒肺炎患者的抗血小板治疗——多即少？
JAMA. 2022 Jan 18;327(3):223-224. doi: 10.1001/jama.2021.23866.
10
Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis.不同抗凝方案对 COVID-19 住院患者死亡率和出血的影响：一项系统评价和更新的荟萃分析。
Semin Thromb Hemost. 2021 Jun;47(4):372-391. doi: 10.1055/s-0041-1726034. Epub 2021 Apr 13.
引用本文的文献
1
Short-term safety and efficacy of aspirin in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.阿司匹林用于新冠肺炎患者的短期安全性和疗效：随机对照试验的系统评价和荟萃分析
PeerJ. 2025 May 21;13:e19466. doi: 10.7717/peerj.19466. eCollection 2025.
2
Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study.COVID-19 住院患者肝脏损伤与疾病进展标志物与死亡率和机械通气风险的关系：一项全国性回顾性 SARSTer 研究。
Viruses. 2024 Sep 27;16(10):1530. doi: 10.3390/v16101530.
3
Anticoagulant use before COVID-19 diagnosis prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis.新冠病毒病诊断前使用抗凝剂能否预防新冠病毒病相关急性静脉血栓栓塞：一项系统评价与荟萃分析
World J Methodol. 2024 Sep 20;14(3):92983. doi: 10.5662/wjm.v14.i3.92983.
4
Retrospective evaluation of acute kidney injury in paediatric COVID-19 patients: a tertiary referral hospital experience.儿童新型冠状病毒肺炎患者急性肾损伤的回顾性评估：一家三级转诊医院的经验
J Nephrol. 2024 Dec;37(9):2541-2550. doi: 10.1007/s40620-024-01986-9. Epub 2024 Jul 20.
5
A Retrospective Study on the Outcome of Coronavirus Disease 2019 (COVID-19) Patients Admitted to a District General Hospital and Predictors of High Mortality.关于一家地区综合医院收治的2019冠状病毒病（COVID-19）患者的结局及高死亡率预测因素的回顾性研究。
Cureus. 2024 Feb 1;16(2):e53432. doi: 10.7759/cureus.53432. eCollection 2024 Feb.
6
Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis.新型冠状病毒肺炎（COVID-19）诊断后抗血小板治疗的效果：系统评价、荟萃分析和试验序贯分析。
PLoS One. 2024 Feb 1;19(2):e0297628. doi: 10.1371/journal.pone.0297628. eCollection 2024.
7
Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data.**药物处方模式及其与 COVID-19 患者死亡率和住院时间的关系：大数据洞察。**
Front Public Health. 2023 Dec 18;11:1280434. doi: 10.3389/fpubh.2023.1280434. eCollection 2023.
8
Coagulopathy and thromboembolic events a pathogenic mechanism of COVID-19 associated with mortality: An updated review.凝血功能障碍和血栓栓塞事件是 COVID-19 相关死亡率的发病机制：最新综述。
J Clin Lab Anal. 2023 Jun;37(11-12):e24941. doi: 10.1002/jcla.24941. Epub 2023 Jul 11.
9
Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.利伐沙班与肝素预防性治疗中重度 COVID-19 的初始治疗性抗凝比较：COVID-PREVENT 随机对照试验结果。
Clin Res Cardiol. 2023 Nov;112(11):1620-1638. doi: 10.1007/s00392-023-02240-1. Epub 2023 Jul 5.
10
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.感染新冠病毒的癌症和心血管疾病患者的新冠严重程度及心血管结局
Transl Oncol. 2023 Aug;34:101709. doi: 10.1016/j.tranon.2023.101709. Epub 2023 Jun 2.
本文引用的文献
1
The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis.新型冠状病毒病严重程度与心血管疾病及其传统危险因素的关系：系统评价和荟萃分析。
Glob Heart. 2020 Sep 22;15(1):64. doi: 10.5334/gh.814.
2
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
3
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.COVID-19 和凝血：SARS-CoV-2 感染的出血和血栓形成表现。
Blood. 2020 Jul 23;136(4):489-500. doi: 10.1182/blood.2020006520.
4
Thrombotic risk in COVID-19: a case series and case-control study.COVID-19 中的血栓风险：一项病例系列和病例对照研究。
Clin Med (Lond). 2020 Jul;20(4):e76-e81. doi: 10.7861/clinmed.2020-0228. Epub 2020 May 18.
5
Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.新冠病毒肺炎住院患者治疗剂量抗凝与院内生存的相关性
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124. doi: 10.1016/j.jacc.2020.05.001. Epub 2020 May 6.
6
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.确认 COVID-19 重症 ICU 患者的血栓并发症累积发生率较高：更新分析。
Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.
7
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
8
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.新型冠状病毒肺炎重型患者静脉血栓栓塞症发病情况。
J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
9
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.REMAP-CAP（社区获得性肺炎的随机嵌入式多因素适应性平台）研究。原理与设计。
Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD.
10
[Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].严重急性呼吸综合征与2019冠状病毒病的临床和病理特征比较
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jun 12;43(6):496-502. doi: 10.3760/cma.j.cn112147-20200311-00312.
Zotero 插件